Oncimmune (LON:ONC) Stock Price Down 5.6% – Time to Sell?

Oncimmune Holdings plc (LON:ONC)’s stock price fell 5.6% during trading on Tuesday . The company traded as low as GBX 1.70 ($0.02) and last traded at GBX 1.70 ($0.02). 202,924 shares traded hands during trading, a decline of 67% from the average session volume of 619,508 shares. The stock had previously closed at GBX 1.80 ($0.02).

Oncimmune Trading Down 11.1 %

The firm has a 50 day moving average price of GBX 9.43 and a two-hundred day moving average price of GBX 13.97. The company has a debt-to-equity ratio of -412.06, a quick ratio of 0.63 and a current ratio of 1.14. The firm has a market capitalization of £1.36 million, a P/E ratio of 0.14 and a beta of 1.19.

Oncimmune (LON:ONC) last released its quarterly earnings results on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share (EPS) for the quarter. Oncimmune had a net margin of 581.63% and a negative return on equity of 2,277.74%.

About Oncimmune

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.